

Development of a new guidance for reporting on indirect comparisons

16th Industry Stakeholder Platform on R&D support

Artur Lewandowski & Anouk Neven




Why indirect comparisons?

Recall the third criterion: [...] *if such a method already exists, the medicine must be of significant additional benefit*[...].

Potential approaches: Side-by-side, Matched Adjusted Indirect Comparisons (MAIC), Network Meta-Analysis (NMA), ...

Evidence Networks



In general, we feel that we see an **increasing use** of quantitative approaches

But...

'Intransparent' and **'heterogeneous'** reporting (see next slides)

Guidance development: Q&A on indirect comparisons

- Collaboration across MWP, COMP and CHMP (referenced in MWP workplan [Methodology Working Party Workplan 2026-2028 - Adopted](#))
- No regulatory documents exist; HTAs have guidance (HTA CG [link 1](#), [link 2](#); NICE DSU [TSD18](#))
- Focus on **improving the reporting**, not on evidentiary standards or permissive contexts
- Main use case is significant benefit and the COMP, but can also be of relevance in other assessments (e.g. conditional marketing approval by CHMP)

The screenshot shows a document template from the European Medicines Agency (EMA) for 'Questions and Answers on indirect comparisons'. It includes a header with the EMA logo and name. The document is dated 29 June 2023 and references EMA/373361/2005. It contains a table for key dates: 'Agreed by <Working Party>' (Month YYYY), 'Adopted by <Committee> for release for consultation' (DD Month YYYY¹), 'Start of public consultation' (DD Month YYYY²), and 'End of consultation (deadline for comments)' (DD Month YYYY³). Below the table, it states that the proposed guideline will replace '<guideline/>title' (EMA/./...)⁴. A section for 'Comments' is provided, with a note to use the EUSurvey form and contact EUSurvey Support for technical issues. A 'Keywords' field is also present. The main body of the document is titled '1. Background' and contains text about indirect comparisons, stating that they are sometimes submitted and assessed in the context of orphan maintenance procedures, but this document does not address regulatory acceptability. It mentions that the document focuses on the expected reporting of indirect comparisons in documents submitted to the EMA if the applicant decides to use indirect comparisons to support their claim. Footnotes at the bottom define the superscripted numbers: ¹ Last day of relevant Committee meeting/Date of PRM adoption, ² Date of publication on the EMA public website, ³ Last day of the month concerned, ⁴ If this supersedes a previous guideline – otherwise delete. It also states that keywords represent an internet search tool and that the document is for internal use only. The footer includes the EMA logo, name, and contact information, along with a copyright notice for 2023.

Evaluating ITC use in orphan maintenance procedures


We evaluated **all orphan maintenance procedures** initiated between 2023 to 2025 to analyse ITC use and reporting.

From initial submissions we extracted:


- Type of ITC method used
- Presence of ITC-specific reporting elements
- Issuance of List of Questions (LoQ)
- Procedural outcome

The goal was to review current practices and reporting by sponsors and to identify potential areas of improvement.


Flowchart (1)



Flowchart (2)




Flowchart (3)



Reporting elements completeness per ITC method

	IC Method			
	Naïve SBS (n = 30)	MAIC (n = 16)	NMA (n = 7)	Bucher (n = 2)
Baseline	63%	94%	43%	100%
Prespecification	0%	0%	0%	0%
Assumption justification	27%	75%	43%	100%
Sensitivity analyses		56%	43%	0%
Missing data addressed	7%	44%	14%	50%
ICE compared	0%	0%	14%	0%
Matching listed		100%		
Matching justification		69%		
ESS provided		88%		
Weights provided		38%		
Network structure			86%	
Prior given			43%	
Prior justified			14%	
⊗ Heterogeneity assessed			50%*	



□ White cell = Element not applicable for this IC method

Reporting elements completeness per ITC method



□ White cell = Element not applicable for this IC method

Reporting elements completeness per ITC method



□ White cell = Element not applicable for this IC method

Reporting elements completeness per ITC method



□ White cell = Element not applicable for this IC method

Reporting elements completeness per ITC method



□ White cell = Element not applicable for this IC method

Reporting elements completeness per ITC method



□ White cell = Element not applicable for this IC method

Conclusions

- The reporting standards are **heterogenous**. Reports range from a single paragraph with a point estimate (and CI) to 100+ page ITC reports done by contractors.
- Procedures requiring evidence of significant benefit are commonly associated with issuance of LoQ, mostly driven by lack of transparency and incomplete reporting.
- The **Q&A on indirect comparisons** and the upcoming **publication on ITC use** in orphan maintenance procedures will strive to improve the current practices.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

anouk.neven@ema.europa.eu

artur.lewandowski@trainee.ema.europa.eu

Follow us



Back-up slide (ESS and MAICs)

